S Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood Drugs Exp Clin Res 1999;25(1):23–28 74 Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, et al Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders Pediatr Nephrol 2009;24(6):1205–1210 75 Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+c1007g, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 2005;15(7):513–522 76 Niemi M, Schaeffeler E, Lang T, et al High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 2004;14(7):429–440 77 Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet Genomics 2006;16(12):873– 879 78 Voora D, Shah SH, Spasojevic I, et al The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 2009;54(17):1609–1616 79 Group SC, Link E, Parish S, et al SLCO1B1 variants and statin-induced myopathy–a genomewide study N Engl J Med 2008;359(8):789–799 80 Tachibana-Iimori R, Tabara Y, Kusuhara H, et al Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors Drug Metab Pharmacokinet 2004;19(5):375–380 81 Li JH, Suchindran S, Shah SH, et al SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization Pharmacogenomics 2015;16(5):449–458 82 Dai R, Feng J, Wang Y, et al Association between SLCO1B1 521 TC and 388 AG polymorphisms and statins effectiveness: a Meta-analysis J Atheroscler Thromb 2015;22(8):796–815 83 Thompson JF, Man M, Johnson KJ, et al An association study of 43 SNPs in 16 candidate genes with atorvastatin response Pharmacogenomics J 2005;5(6):352–358 84 Ramsey LB, Johnson SG, Caudle KE, et al The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update Clin Pharmacol Ther 2014;96(4):423–428 85 Wagner JB, Abdel-Rahman S, Van Haandel L, et al Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics J Clin Pharmacol 2018;58(6):823–833 86 Wagner J, Van Haandel L, Raghuveer G, et al Pharmacokinetics of pravastatin in pediatric dyslipidemia: clinical impact of genetic variation on statin disposition Circulation 2015;132(suppl):A13716 [Abstract] 87 Till JA, Shinebourne EA, Rowland E, et al Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics Br Heart J 1989;62(2):133– 139 88 Zeigler V, Gillette PC, Ross BA, Ewing L Flecainide for supraventricular and ventricular arrhythmias in children and young adults Am J Cardiol 1988;62(10 Pt 1):818–820 89 Flecainide versus quinidine for treatment of chronic ventricular arrhythmias A multicenter clinical trial Circulation 1983;67(5):1117– 1123 ... Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics J Clin Pharmacol 2018;58(6):823–833 86 Wagner J, Van Haandel L, Raghuveer G, et al Pharmacokinetics of pravastatin in pediatric dyslipidemia: clinical impact of genetic variation